Malformations of cortical development (MCDs) are increasingly recognized as an important cause of autism, neurodevelopmental delay and epilepsy, especially medically intractable 'catastrophic' epilepsy. Disruption of cortical development at various critical stagessuch as neuronal proliferation, migration and organization-leads to characteristic MCD. FMCDs are characterized by localized cortical and subcortical lesions 1,2 . At the most severe end of the spectrum is hemimegalencephaly (HME), a clinically devastating pediatric FMCD characterized by enlargement of most or all of one entire cerebral hemisphere. Individuals with HME typically present with epilepsy, psychomotor disability and contralateral hemiparesis 3 . Most affected individuals display progressive and catastrophic epilepsy, which invariably requires radical hemispherectomy (i.e., removal of the affected cerebral hemisphere) as a surgical treatment to relieve epilepsy and to prevent further psychomotor disability.
Malformations of cortical development (MCDs) are increasingly recognized as an important cause of autism, neurodevelopmental delay and epilepsy, especially medically intractable 'catastrophic' epilepsy. Disruption of cortical development at various critical stagessuch as neuronal proliferation, migration and organization-leads to characteristic MCD. FMCDs are characterized by localized cortical and subcortical lesions 1, 2 . At the most severe end of the spectrum is hemimegalencephaly (HME), a clinically devastating pediatric FMCD characterized by enlargement of most or all of one entire cerebral hemisphere. Individuals with HME typically present with epilepsy, psychomotor disability and contralateral hemiparesis 3 . Most affected individuals display progressive and catastrophic epilepsy, which invariably requires radical hemispherectomy (i.e., removal of the affected cerebral hemisphere) as a surgical treatment to relieve epilepsy and to prevent further psychomotor disability.
FMCDs are characterized by cortical dyslamination and ectopic neurons in the subcortical white matter and, in the most severe form of disease, are associated with the presence of dysmorphic, cytomegalic neurons and 'balloon cells' 4, 5 . The lesions are consistent with recent models of brain mosaicism 6 . Because some FMCD lesions show pathological features similar to those of tuberous sclerosis complex (TSC)-related cortical tubers (i.e., the presence of phosphorylated ribosomal protein S6 (pS6), a downstream component of mTOR activation) 3 , mutations in the mTOR pathway were anticipated.
Recently, postzygotic brain-specific somatic mosaic mutations in PIK3CA, AKT3 and MTOR were identified in FMCDs 1, [7] [8] [9] [10] . Mutations were found in 8-30% of cells and were some of the same gain-offunction activating mutations that were seen in solid malignancies, including glioblastoma multiforme (GBM). Sequencing at the singlecell level identified a mutation burden in both neural and nonneural cells, indicating that mutations occur in progenitors 11 . However, the mechanisms of disease and the potential for treatment remain poorly defined. Moreover, the mechanism by which a relatively small percentage of cells with a mutation can disrupt the organization of the entire hemisphere is mostly unknown 12 .
RESULTS

Mosaic mutation is restricted to cells with mTOR activation
We focused on AKT3, a commonly mutated gene in FMCD 1, 7, 8, 13 . To test whether pS6 + cells were enriched for the mosaic mutation, a r t i c l e s 1 4 4 6 VOLUME 21 | NUMBER 12 | DECEMBER 2015 nature medicine we studied a human FMCD brain tissue sample with a somatic gainof-function mutation (c.49G>A; p.E17K-and we hereafter refer to the mutated gene as AKT3 E17K ) that was present in 19.1% of the measured alleles on the basis of mass spectrometric analysis (Fig. 1a-c) 1 . Laser-captured microdissection of pS6 + versus pS6 − neural cells was followed by PCR, capillary sequencing and single-base extension mass spectrometry to test for the mutant allele. Analysis of captured cells showed that the mutant allele was undetectable in pools of pS6 − cells, whereas pS6 + cells of the same brain section were enriched for the mutation, which was detected in 36.8% of measured alleles. We conclude that pS6 is a sensitive but not specific marker for cells carrying the mutation, suggesting that activation of the pathway is relevant to the pathogenesis of disease.
Mouse model of focal malformations of cortical development
To test whether introduction of the AKT3 E17K FMCD-associated mutation is sufficient to cause neurodevelopmental and neuropathological features, we electroporated a vector encoding AKT3 E17K , which is found in at least two persons with FMCD, into the right hemisphere of embryonic day (E) 14.5 mice. We chose this model because we could limit the expression of AKT3 to the neural progenitors of a single hemisphere, mimicking the somatic postzygotic mosaicism found in the embryonic brains of individuals with FMCD ( Supplementary  Fig. 1a ). Electroporations were timed to predominantly target neurons destined for upper cortical plate (uCP) layer II/III, the cells proposed to be most severely affected in FMCD 14, 15 . Histological examinations of mouse brains at postnatal day (P) 20 revealed key features that are observed in FMCD, including neuronal heterotopias, dysmorphic neurons with enlarged soma and neuronal crowding (Fig. 1d-g ) 3 . Whereas only 5.6% ± 3.9% of cells that were electroporated with a control vector (expressing green fluorescent protein (GFP) as a marker) failed to reach uCP layers II/III and IV, 16.3% ± 1.6% and 55.5% ± 7.0% of cells that were electroporated with human wild-type AKT3 (i.e., overexpression; hereafter referred to as AKT3 OE ) or with AKT3 E17K , respectively, were misplaced in the middle cortical plate layer (mCP, layer V), the lower cortical plate layer (loCP, layer VI) or the subventricular zone (SVZ). Misplaced cells in the SVZ expressed neuronal markers (such as NeuN) but not glial markers (such as GFAP). No anatomical changes in the contralateral hemisphere were found. The most devastating pathologies of FMCD are early onset seizures, which are often medically intractable 3 . Mice electroporated with wildtype AKT3 OE or AKT3 E17K showed higher perinatal lethality (11.9% for vector control, n = 42; 24.3% for AKT3 OE , n = 37; and 67.0% for AKT3 E17K , n = 103), suggesting that seizures might be a cause for the increased lethality. Electroencephalogram (EEG) recordings of AKT3 E17K mice showed recurrent and unprovoked excessive electrical activity (Fig. 1h-j) . In contrast, EEG recordings of control mice showed no such activity, whereas those of AKT3 OE mice showed only occasional bursts of shorter duration. An inflammatory response in the form of activated microglia was not apparent, suggesting that disrupted neuronal circuitry or activity was probably a cause for the observed EEG patterns.
Developmental neuropathology results from AKT3 activation
Although clinical epilepsy may have numerous underlying cellular and molecular mechanisms, the investigation of epileptogenesis in FMCD has mostly focused on intracortical and corticothalamic projections 16 . Examination of the axonal projections of the electroporated neurons in mice showed only typical subcortical projections (data not shown). Furthermore, we found no gross changes in inhibitory neurons, as evidenced by the number or distribution of cells expressing GAD1 and GAD2 (enzymes that catalyze decarboxylation of glutamate to γ-aminobutyric acid) in the mice electroporated with AKT3 E17K as compared to those with the control vector.
We next examined whether cell fate was altered by AKT3 E17K expression. We used the layer-specific markers SATB2 (for uCP) and CTIP2 (for mCP) to examine cortical cell positioning in developing brains and confirmed defective neuronal migration at E18.5 ( Supplementary Fig. 1b,c) . We found no changes in the integrity of radial glia, as assessed by expression of brain lipid-binding protein (BLBP), in the electroporated regions of the developing brain (data not shown). In control vector-electroporated brains, 96% of GFP + cells were SATB2 + CTIP2 − , thus showing uCP identity. AKT3 OE -or AKT3 E17K -electroporated neurons were also predominantly SATB2 + CTIP2 − (93% and 96%, respectively), but the cells were localized to the loCP (Supplementary Fig. 1d,e) . These data suggest that despite the migration defect, birthdatespecified identity was not altered.
To test neuronal migration defects in humans, we used human neural progenitor cells (hNPCs) that were differentiated from induced pluripotent stem cells (iPSCs) from a healthy donor. We selected hNPCs because they are derived from humans, have been well studied and can express markers of both differentiating and migrating neurons depending upon the type of media used for culture 17, 18 . The hNPCs were transduced with a lentivirus expressing either red fluorescent protein (RFP) alone or AKT3 E17K with RFP and were then sorted for similar fluorescent intensities using FACS. In propagation medium, approximately 4.6% ± 1.1% of control hNPCs expressed the neuronal differentiation marker MAP2, whereas 10.3% ± 3.1% of AKT3 E17K -expressing hNPCs were MAP2 + . When cultured in differentiation medium, again about twice as many AKT3 E17K hNPCs were MAP2 + , as compared to the control hNPCs (Fig. 2a,b) , suggesting that presence of the mutation leads to premature differentiation. This was confirmed in E18.5 mouse brains, in which GFP + MAP2 + neurons were found below the subplate in AKT3 E17K -electroporated brains but not in vector control-electroporated brains (Supplementary Fig. 1f ).
In neurosphere migration assays, control neurons had migrated 113.8 µm ± 29.0 µm from the neurosphere edge after 2 d, whereas neurons of AKT3 E17K -expressing neurospheres were densely located near the edge and had migrated 30.9 µm ± 5.1 µm (Fig. 2c,d ). Moreover, MAP2 + neurons in AKT3 E17K -expressing neurospheres were often misoriented and failed to display typical migration morphology. Thus, the premature differentiation of AKT3 E17K -expressing neurons may contribute to the migration defects.
Requirement of AKT3 kinase activity
To investigate the requirement of AKT3 kinase activity in mediating neuronal migration deficits in vivo, we used in utero electroporation of human AKT3 E17K constructs that either contained or did not contain an additional K177M mutation, which renders AKT3 null for kinase activity. The kinase domain mutation in AKT3 E17K K177M abolished not only the neuronal migration defects observed in AKT3 E17K brain sections but also the hyperphosphorylation of the downstream target pS6 (Fig. 3a-c) , suggesting a requirement for kinase activity in cellular defects of neurons. Furthermore introducing an alanine mutation at residue S472 (AKT3 S472A ), a phosphorylation site critical for AKT3 activation, also prevented pathology ( Supplementary  Fig. 2a,b) . Conversely, a mutation that mimics phosphorylation (AKT3 S472E ) and activates downstream signaling caused migration defects similar to that of AKT3 E17K . We additionally tested the effect of overexpressing human wild-type or a gain-of-function mutant of PIK3CA (PIK3CA OE or PIK3CA E545K , respectively), the gene encoding PI3K that we and others have reported to be mutated in FMCD and other segmental overgrowth syndromes 1, 7 , and observed neuronal migration defects and dysmorphic neurons with enlarged soma similarly to that of AKT3 E17K ( Supplementary Fig. 2c-f) . Activation of PI3K in the developing cortex by inducing the expression of PIK3CA H1047R , another gain-of-function mutation of PIK3CA found in FMCD, by using a germline knock-in allele 19 and in utero hemispheric electroporation of a Cre-containing plasmid, also caused similar neurodevelopmental defects (data not shown). Notably, the neuronal migration defect in brains electroporated with PIK3CA E545K was almost completely prevented by co-expression of the kinase-null AKT3 K177M ( Supplementary  Fig. 2c,d ), consistent with a linear signaling pathway in the etiology of FMCD. Therefore, the migration defect is not allele or gene specific but rather is due to hyperactivation of the PI3K-AKT3 pathway.
Developmental rescue of neuronal defects
To test whether inhibition of the AKT3 downstream pathway could prevent the migration defect, we administered rapamycin, a potent inhibitor of mTOR signaling, to pregnant dams for 4 d after electroporation of the AKT3 constructs (Supplementary Fig. 3a) . Rapamycin treatment effectively rescued AKT downstream activation in the developing cortex, as assessed by pS6 immunostaining. It also rescued, for the most part, the cortical dyslamination resulting from aberrant neuronal migration (as assessed by MAP2 immunostaining) as well as the enlarged soma size (Fig. 4a-e and Supplementary Fig. 3b,c) . However, postnatal treatment with rapamycin at P1 and P3 did not restore the neuronal migration defect caused by AKT3 E17K (data not shown), suggesting that there is a specific window during development for the drug to act.
Non-cell autonomous effect on migration
In AKT3 OE -and AKT3 E17K -electroporated hemispheres, we noticed that an ectopic layer of SATB2 + neurons in the intermediate zone (IZ) or the SVZ also included cells that were GFP − ( Supplementary  Fig. 1b,e) , suggesting an effect of the mutant cells on neighboring wild-type cells. To explore potential non-cell autonomous migration defects, we performed sequential in utero electroporation experiments 20 of a vector expressing RFP followed by the AKT3 E17K construct that also expresses GFP, and found that AKT3 E17K -expressing (i.e., RFP − GFP + ) cells affected the migration of neighboring (i.e., RFP + GFP − ) cells (Fig. 5a,b) . Bromodeoxyuridine (BrdU) birthdating analysis from E14.5 injections demonstrated the presence of duallabeled (i.e., BrdU + GFP + ) ectopic AKT3 OE -or AKT3 E17K -expressing cells in mCP or loCP, suggesting that the misplaced cells underwent DNA synthesis concomitant with other cells that were destined for the upper cortical layers (Supplementary Fig. 4a,b) . Additionally, no significant difference in proliferation or apoptosis rates was detected in migrating neurons (data not shown). Increased numbers of GFP − cells that were BrdU + in the loCP of brains expressing either AKT3 OE or AKT3 E17K were also observed (Supplementary Fig. 4c ). Together, these results suggest an effect of AKT3 E17K -expressing cells on the migration of neighboring cells.
Functional networks underlying FMCD
The non-cell autonomous migration defect may be due to physical blockade of wild-type cells trying to migrate past mutant cells, or it may have more specific signaling mechanisms. The AKT3 E17K mutation was introduced in hNPCs via lentiviral transduction using the pBOBSwitch vector, which allows for Cre-mediated recombination of the cDNA cassette (Fig. 5c) . To obtain homogeneous AKT3 E17K -expressing hNPCs, we used FACS to collect cells that were expressing RFP at similar intensities (Supplementary Fig. 5a ), immediately isolated RNA from them and performed RNA-seq expression profiling. We identified 835 genes whose expression was significantly altered (false discovery rate-corrected P < 0.05) in AKT3 E17K -expressing cells, as compared with empty vector-containing cells. These included several genes that were previously reported to be downstream of AKT signaling-such as CDKN2A (encoding the tumor suppressors p16 INK4a and p14 ARF ), CDKN2B (encoding the tumor suppressor p15 INK4b ) and CCND1 (encoding cyclin D1)-suggesting robust methodology. Network analysis of the 835 genes using gene ontology (GO) enrichment analysis revealed that they could be classified into four major categories-those involved in: (i) neuronal development, (ii) migration, (iii) signaling and homeostasis and (iv) cell cycle regulation ( Fig. 5d and Supplementary Fig. 5b ).
Genetic rescue identifies reversible FMCD network
To determine the reversibility of the molecular changes induced by the FMCD-associated mutations, Cre recombinase was introduced by adenoviral transduction into hNPCs to remove the AKT3 E17K -RFP cassette. Cre recombination also removed the stop codon located 5′ to the GFP start site, thus enabling visualization of the recombined cells using GFP expression (Supplementary Fig. 5c ). Upon Cre expression, the AKT3 transcript level was restored to its basal level (Fig. 5e) , suggesting efficient genetic recombination that correlated with color switching from red to green. Repeating the RNA-seq analysis identified that 275 of 835 genes (i.e., one-third) were persistently misexpressed, whereas the majority 560 genes (i.e., two-thirds) showed changes that either restored expression to wild-type levels or altered gene expression in the opposite direction.
Critical role of reelin in developmental pathogenesis
The rescue of the migration defect after mice were treated with rapamycin suggested that the pathway that was disrupted by AKT3 E17K expression was reversible, and thus we focused on the set of genes in hNPCs that restored expression following Cre recombination. Among these, RELN, which encodes the reelin secreted glycoprotein 20 that is essential for neuronal migration and lamination during cortical development [21] [22] [23] [24] , was the most significantly affected gene (P < 0.00005) and was dramatically upregulated. Loss of RELN leads to profound defects in neuronal positioning and dendritogenesis in human and mouse brains 25 , whereas ectopic expression in migrating neurons induces neuronal ectopia 26, 27 . We confirmed increased expression (~tenfold) of RELN in AKT3 E17K hNPCs (Fig. 6a) . In AKT3 E17K -expressing brains, reelin was detected in excessive amounts and localized to perisomal regions close to ectopic neurons (Fig. 6b) . Reelin misexpression by AKT3 E17K expression was not detected in P20 brain sections, suggesting that the pathogenic mechanisms are limited to a specific developmental window (Supplementary Fig. 6a ). We also examined the expression of RELN in pS6 + versus pS6 − cells that were microdissected from surgically resected FMCD human brain lesions that were positive for the somatic AKT3 E17K mutation and confirmed RELN expression in only one of four pools of the pS6 + cells (Supplementary Fig. 6b) . We conclude that reelin misexpression resulting from the presence of AKT3 E17K is mostly limited to developing, rather than mature, neurons.
Reelin is initially expressed throughout in the cortical anlage at the preplate stage (E9.5), but after E11.5, its expression is mainly restricted to the Cajal-Retzius cells of the marginal zone. Therefore, we tested the degree to which defective migration in AKT3 E17K -expressing cells and its neighboring cells was due to the misexpression of reelin in ectopic regions, by using knockdown of Reln in cells that were electroporated with human AKT3 E17K . In utero electroporation of Reln siRNA constructs into cortical progenitors alone produced no defect in migration, supporting its role in specialized Cajal-Retzius cells at this time point. However, the migration defect of AKT3 E17K -expressing neurons was partially but significantly restored (P < 0.001) by the co-electroporation of siRNA targeting Reln (Fig. 6c,d) , suggesting that overexpression of Reln siRNA in AKT3 E17K cells leads to an autocrine or paracrine effect. To test specifically for a paracrine effect of reelin on neuronal migration, sequential electroporation of an RFP-containing construct followed by a mixture of a construct expressing AKT3 E17K and siRNA targeting Reln was done such that the RFP-expressing cells should no longer be exposed to ectopic reelin produced by the GFP + AKT3 E17K -expressing cells. This nearly fully rescued the non-cell autonomous migration defects (Fig. 6e,f) , suggesting a central role for ectopic reelin expression in the etiology of the migration defect in AKT3 E17K -expressing brains.
Reelin misregulation by activation of the AKT3-FOXG1 pathway To investigate the mechanism by which AKT3 regulates reelin expression, we looked for commonalities in genes that were altered by AKT3 E17K expression but restored after Cre recombination. We found that among the genes meeting this criterion, there was an overrepresentation of genes with binding sites for FOX transcription factors that were present up to 5 kb upstream of the transcription start site (P = 1.3 × 10 −6 ) (Fig. 6g) . RFP is expressed from a bicistronic 2A sequence that encodes the self-cleaving 2A peptide and allows for stoichiometric expression of RFP and AKT3 E17K . LTR, long terminal repeat; CAG, chicken actin promoter. The loxP site-flanked RFP expression cassette (along with the stop codon) is removed upon Cre recombination after adenoviral transduction, providing a color switch due to expression of GFP instead of RFP. (d) GO analysis identified four major enriched categories (neuronal development, migration, signaling and homeostasis, and cell cycle regulation) and several subcategories as indicated. P values for GO enrichment for each subcategory are shown (x axis). Colors indicate P values of the GO enrichment for the portion of the genes within each subcategory that persisted (dark blue) or that were restored (i.e., from high to background levels or from low to background levels) or reversed (i.e., from high to low levels or from low to high levels) (light blue), overlaid on each subcategory. (e) Comparison of mRNA levels in cells overexpressing AKT3 E17K (x axis) versus those in cells in which AKT3 E17K was genetically removed by Cre recombination (AdCre induction, y axis). Note that the expression of AKT3 and RELN were initially elevated with AKT3 E17K overexpression but were restored upon Cre recombination. In mice, Foxg1 controls the morphogenesis of the telencephalon 29 , and mutants show increased numbers of reelin-expressing CajalRetzius cells 30 . Under basal conditions, FOX factors act as transcriptional repressors, but after phosphorylation by AKT, the FOX proteins translocate to the cytoplasm, thereby inhibiting their transcriptional repressor activity 31 . Thus, we searched for conserved FOX-binding sequences and identified four potential sites (R1-R4) upstream of RELN. Chromatin immunoprecipitation demonstrated that FOXG1 was significantly enriched (P < 0.001) in two sites that have two FOX-binding sites each (Supplementary Fig. 6c ). Next we confirmed the cytoplasmic localization of FOXG1 in hNPCs expressing AKT3 E17K (Supplementary Fig. 6d,e) . In NIH 3T3 cells, a Foxg1-GFP fusion protein predominantly localized to the nucleus; however, co-expression with AKT3 E17K induced cytoplasmic translocation of the fusion protein (Supplementary Fig. 6f,g) . Mutation of the putative T271 phosphorylation site to a nonphosphorylatable alanine (Foxg1 T271A ) abolished AKT3 E17K -induced cytoplasmic translocation of Foxg1. Conversely, the phosphomimetic glutamic acid mutant (Foxg1 T271E ) increased cytoplasmic localization. Furthermore, increased RELN transcription in AKT3 E17K hNPCs was repressed by the expression of Foxg1 T271A (Supplementary Fig. 6h ). Similar to the effects observed with Reln siRNA, co-electroporation of Foxg1 T271A in the developing brain partially rescued the migration defects caused by AKT3 E17K expression (Fig. 6c,d ). These findings suggest that AKT3 mediates FOXG1 phosphorylation-dependent derepression of RELN transcription.
DISCUSSION
A major focus in neuroscience is the improved care of individuals with intractable epilepsy. The observation that the vast majority of patients undergoing surgical resection of FMCDs become seizure free and show cognitive stabilization or improvement 32 indicates that the focus for the neurocognitive defects most frequently resides within the lesion.
Here we demonstrate that postzygotic mutations that were identified in FMCDs are restricted to cells showing activation of the PI3K-AKT3 pathway and are sufficient to recapitulate the disrupted neuronal migration, excessive neuronal size, altered differentiation and epileptiform activity observed in FMCDs. We asked how somatic mutations in just a small percentage of cells could produce such severe and widespread defects in brain development. Profiling of mRNAs that were differentially expressed in AKT3 E17K -expressing brains pointed to the ectopic misexpression of reelin, which we found to be due (at least in part) to the AKT3-mediated phosphorylationdependent inactivation of Foxg1 (through its relocalization to the cytoplasm), leading to derepression of RELN expression in the developing brain (Fig. 6h) .
A role for the mTOR pathway in brain development was first proposed from work in tuberous sclerosis complex (TSC) 33 and was later demonstrated through conditional removal of key regulators of the mTOR pathway, such as Pten, Tsc1 and Tsc2 (refs. [34] [35] [36] . The emerging consensus is that activation of the pathway leads to neuronal hypertrophy, excessive dendritic branching and a cell typespecific effect on excitability, whereas inhibition shows the opposite effects [37] [38] [39] . Recently there has been a focus on the mTOR pathway in autism, because of both the striking autistic features displayed by persons with monogenic syndromic mTORopathies and the evidence of mutations in the mTOR pathway in individuals with nonsyndromic forms of autism 40 . This connection is supported by animal models with a forebrain-specific deletion of Pten or a cerebellar-specific deletion of Tsc1, resulting in marked abnormalities of social behavior 41, 42 . The data suggest that germline or widespread somatic mutations may result in overt structural brain defects, whereas subtle, cell type-specific or mosaic mutations may result in restricted phenotypes.
De novo heterozygous mutations in FOXG1 are present with a congenital variant of Rett syndrome with a generalized cortical malformation 43 , suggesting haploinsufficiency as a disease mechanism, whereas complete deletion in mouse results in near absence of the telencephalon 29 . Notably, whereas humans with homozygous RELN mutations present with a form of lissencephaly 25 , RELN genetic variants in the 5′ untranslated region (UTR) predispose people to autistic disorder 44 . A conceptual advance from our data is that the neuronal cell migration defect observed during brain development is not due to reelin misexpression per se but rather to ectopic misexpression in cortical zones that are not normally exposed to reelin. Knockdown of Reln in developing mouse brain rescued the migration defect not just for the neighboring cells but also for the cells expressing the human AKT3 E17K allele, suggesting an autocrine or paracrine effect of reelin on neuronal migration. Rapamycin rescued the noncell autonomous migration defect-probably because of its effect on cell autonomous migration defects, thus hindering accumulation of reelin in this ectopic location. Because ectopic Reln misexpression was seen in the developing mouse brain but not in the mature brain, this suggests that RELN expression will not be a sensitive marker for cells with mTOR pathway mutations in human cortical resections.
Our results suggest two possible explanations for FMCD-related seizures in humans: cortical dyslamination due to disrupted migration or increased neuronal excitability related to morphological or signaling changes. Although cortical dyslamination can cause neuronal circuitry defects such as abnormal intracortical and corticothalamic projections that are linked to epilepsy 16, 45 , epileptic seizures are traditionally characterized as the synchronous neural hyperactivity arising from imbalanced excitation and inhibition 46 . On the one hand, although reelin signaling regulates dendrite growth 47 and ion channel compartmentalization that contributes to hyperpolarizationactivated cation currents 48 , no epileptic phenotype has been reported in mice in which reelin is either downregulated or overexpressed 49 . On the other hand, hyperactivation of the mTOR pathway can increase neuronal excitation. Thus, the data argue in favor of mTOR pathways having a larger contribution to epilepsy than reelin misexpression in the mTORopathies.
Mutations in the PI3K-AKT pathway have been recognized in brain tumors for a long time, and somatic mutations have been found in upwards of 90% of GBMs 50 . Why then do persons with FMCD with the same mutation not develop tumors? One possibility is that PI3K-AKT pathway-mediated transformation is cell cycle dependent. However, most neuroblasts are actively dividing during periods of migration, so this is unlikely to create a barrier to transformation. Another possibility is that activating mutations are not sufficient for cellular transformation in neural cells, and data certainly support cooperativity among signaling pathways, such as those involving the tumor suppressors p53 and Rb, in the induction of high-grade astrocytomas in adults 50, 51 . In fact, selective activation of mTORC1 (a protein complex that controls protein synthesis) in a specific context produces microcephaly due to massive numbers of cells undergoing programmed cell death 52 . Several human syndromes such as Cowden (Online Mendelian Inheritance in Man (OMIM), 158350), Lhermitte-Duclos, CLOVES (OMIM, 612918), Proteus (OMIM, 176920) and megalencephaly (OMIM, 603387) syndromes demonstrate hamartomatous noncancerous lesions or increased organ size across the body plan, along with mutations predicted to hyperactivate the mTOR pathway 7, 53, 54 . Mouse models in neural progenitors demonstrate roles for the mTOR pathway in determining cellular morphology and size 35, 41 . A picture of segmental overgrowth due to activating mutations is emerging 55 , and in vivo models provide useful tools to study them 10, 56 . Our finding that activating mutations in the PI3K-AKT pathway recapitulate FMCD in a mammalian model sets the stage for further mechanistic studies and development of therapies for these catastrophic disorders.
METhODS
Methods and any associated references are available in the online version of the paper. 
